Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.78
(-0.24%)
CNY 20.78
(-0.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -428.95 Million CNY | -26.52% |
| 2022 | -339.05 Million CNY | 20.53% |
| 2021 | -426.63 Million CNY | 22.64% |
| 2020 | -551.5 Million CNY | -113.52% |
| 2019 | -258.29 Million CNY | -50.47% |
| 2018 | -171.65 Million CNY | 10.55% |
| 2017 | -191.89 Million CNY | -41.54% |
| 2016 | -135.57 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -383.87 Million CNY | 10.51% |
| 2024 Q3 | -29.77 Million CNY | 65.92% |
| 2024 Q2 | -49.25 Million CNY | 87.17% |
| 2023 Q3 | -431.82 Million CNY | -35.1% |
| 2023 FY | -428.95 Million CNY | -26.52% |
| 2023 Q2 | -319.63 Million CNY | 15.42% |
| 2023 Q1 | -377.91 Million CNY | -11.46% |
| 2023 Q4 | -428.95 Million CNY | 0.66% |
| 2022 Q4 | -339.05 Million CNY | -14.11% |
| 2022 Q3 | -297.13 Million CNY | 4.53% |
| 2022 Q2 | -311.21 Million CNY | 22.03% |
| 2022 Q1 | -399.15 Million CNY | 6.44% |
| 2022 FY | -339.05 Million CNY | 20.53% |
| 2021 Q3 | -505.05 Million CNY | -3.45% |
| 2021 Q1 | -497.28 Million CNY | 11.84% |
| 2021 Q4 | -426.63 Million CNY | 15.53% |
| 2021 FY | -426.63 Million CNY | 22.64% |
| 2021 Q2 | -488.18 Million CNY | 1.83% |
| 2020 Q4 | -564.09 Million CNY | 10.98% |
| 2020 FY | -551.5 Million CNY | -113.52% |
| 2020 Q3 | -633.66 Million CNY | -110.87% |
| 2020 Q2 | -300.5 Million CNY | -213.37% |
| 2020 Q1 | 265.05 Million CNY | 200.0% |
| 2019 Q2 | -194.07 Million CNY | 0.0% |
| 2019 Q4 | -265.05 Million CNY | 0.0% |
| 2019 FY | -258.29 Million CNY | -50.47% |
| 2018 FY | -171.65 Million CNY | 10.55% |
| 2017 FY | -191.89 Million CNY | -41.54% |
| 2016 FY | -135.57 Million CNY | 0.0% |